Drug Profile
BHV 5000
Alternative Names: BHV-5000Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Biohaven Pharmaceuticals
- Class Analgesics; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Major depressive disorder; Neuropathic pain
- No development reported Complex regional pain syndromes; Neurological disorders; Rett syndrome
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Rett syndrome(In volunteers) in USA (PO)
- 28 Jan 2024 No recent reports of development identified for phase-I development in Rett syndrome(In volunteers) in USA (PO, Liquid)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Complex-regional-pain-syndromes in USA (PO, Capsule)